In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis

• Published in: Experimental parasitology Vol. 246; p. 108462
• Main Authors: Ferreira, Bianca A., Coser, Elizabeth M., Saborito, Cristiele, Yamashiro-Kanashiro, Edite H., Lindoso, José Angelo L., Coelho, Adriano C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2023
• Subjects: Amphotericin B; Amphotericin B - pharmacology; Amphotericin B - therapeutic use; Antiprotozoal Agents - pharmacology; Antiprotozoal Agents - therapeutic use; Brazil - epidemiology; Drug susceptibility; Humans; Leishmania; Leishmaniasis - drug therapy; Leishmaniasis, Cutaneous - drug therapy; Leishmaniasis, Cutaneous - epidemiology; Leishmaniasis, Cutaneous - parasitology; Miltefosine; Phosphorylcholine - pharmacology; Phosphorylcholine - therapeutic use; Tegumentary leishmaniasis; Brazil; PBS; LRV1; AI; ITS; Drug susceptibility; Tegumentary leishmaniasis; BMDM; DCL; Miltefosine; Amphotericin B; LCL; Leishmania; FBS; AmB; MCL; TL; MF; PCR

Tegumentary leishmaniasis encompasses a spectrum of clinical manifestations caused by the parasitic protozoa of the genus Leishmania. In Brazil, there are at least seven Leishmania species that are endemic and responsible for this set of clinical manifestations of the disease. Current treatment is l...